Biosensor Integrated in Active Microfluidic Cartridge Allows Superior Screening Possibilities
|
By LabMedica International staff writers Posted on 06 Jan 2010 |
A polymer-based sensor integrated into an active microfluidic cartridge will allow simpler, faster, and systematic screening possibilities. The new concept for diagnosis will permit, for example, doctors to diagnose a disease such as cancer, using only few microliters of blood taken from a patient.
The integration of sensing functionality as well as assay functionality into a compact fully-integrated cartridge-like device allowed transferring complexity from the macro to the micro system, leading to a Lab-on a-Chip. A polymer based technology platform was developed; it applies a label-free optical detection based on surface plasmon resonance (SPR).
Integrated into the cartridge the optical components (light source, waveguide, and detector) and fluidic elements for active liquid transport make it very suitable for diagnostics. The final product will be manufactured using large scale, mass production techniques resulting in a cartridge that will be inexpensive, disposable, and sensitive.
The polymer-based sensor the Plasmon enhanced SPR is being developed by the Surface Enhanced Micro Optical Fluidic Systems (SEMOFS) project (Chemnitz, Germany), supported by the European Commission with EUR 1.9 million in funding. The consortium of the project involves multidisciplinary expertise split among eight partners from five European countries, Switzerland, Belgium, Germany, France, and the UK.
SEMOFS was finished in February 2009, and tangible achievements have been reached. The hardware components of the integrated approach are technically operable. The cost estimations show that the cost target of less than EUR 50 is within reach. The concept is considered as being feasible for the new integrated biosensor approach. Some of the aspects targeted in the project need to be studied in more detail; these include the integration of all components into a single device to allow for example, clinical testing for cancer.
In order to begin utilizing project results it will be necessary to apply the components in several different applications, such as: excitation, microfluidic, polymer photodiode array for the low cost spectrometer, fast optimization in plasmonic devices design, and surface coating.
Related Links:
SEMOFS
The integration of sensing functionality as well as assay functionality into a compact fully-integrated cartridge-like device allowed transferring complexity from the macro to the micro system, leading to a Lab-on a-Chip. A polymer based technology platform was developed; it applies a label-free optical detection based on surface plasmon resonance (SPR).
Integrated into the cartridge the optical components (light source, waveguide, and detector) and fluidic elements for active liquid transport make it very suitable for diagnostics. The final product will be manufactured using large scale, mass production techniques resulting in a cartridge that will be inexpensive, disposable, and sensitive.
The polymer-based sensor the Plasmon enhanced SPR is being developed by the Surface Enhanced Micro Optical Fluidic Systems (SEMOFS) project (Chemnitz, Germany), supported by the European Commission with EUR 1.9 million in funding. The consortium of the project involves multidisciplinary expertise split among eight partners from five European countries, Switzerland, Belgium, Germany, France, and the UK.
SEMOFS was finished in February 2009, and tangible achievements have been reached. The hardware components of the integrated approach are technically operable. The cost estimations show that the cost target of less than EUR 50 is within reach. The concept is considered as being feasible for the new integrated biosensor approach. Some of the aspects targeted in the project need to be studied in more detail; these include the integration of all components into a single device to allow for example, clinical testing for cancer.
In order to begin utilizing project results it will be necessary to apply the components in several different applications, such as: excitation, microfluidic, polymer photodiode array for the low cost spectrometer, fast optimization in plasmonic devices design, and surface coating.
Related Links:
SEMOFS
Latest Molecular Diagnostics News
- Blood Test Predicts Immunotherapy Response in Head and Neck Cancer
- New PCR Assay Supports Bundibugyo Ebola Outbreak Surveillance
- Blood-Based RNA Test May Predict Chemotherapy Sensitivity in Lung Cancer
- Plasma Protein Signature Predicts Lung Cancer Risk Up to Five Years Ahead
- Circulating Tumor DNA Testing Guides Chemotherapy, Reduces Relapse in Colon Cancer
- Researchers Uncover Distinct Chromosome Signature in Aggresive ALT Cancers
- Simple Cytogenetic Method Could Improve Classification of ALL Subtypes
- Blood-Based Assay Enables Noninvasive Monitoring of Sarcoma Immunotherapy Response
- Genomic Test Guides Chemotherapy Decisions in Early-Stage Breast Cancer
- Tumor Mutation Marker Helps Refine Lung Cancer Prognosis and Guide Therapy Selection
- Multi-Cancer Test Boosts Detection When Added to Standard Screening
- Blood-Based MRD Monitoring Supports Relapse Prevention in Leukemia
- Genomic Test Predicts Chemotherapy Benefit in Metastatic Prostate Cancer
- Blood Protein Markers Flag Multiple Sclerosis Risk Years Before Diagnosis
- Digital PCR Assays Support Surveillance of Bundibugyo Ebolavirus Outbreak
- Updated Guidance Prioritizes Stool-Based Colorectal Cancer Screening Tests
Channels
Clinical Chemistry
view channel
Urinary Biomarker Assay Predicts Kidney Disease Progression Beyond Standard Measures
Many patients with type 2 diabetes and chronic kidney disease continue to experience progressive renal decline, yet conventional markers such as albuminuria and estimated glomerular filtration rate (eGFR)... Read more
Saliva-Based Test Detects Biochemical Signs of Sleep Loss
Acute sleep loss impairs cognition and motor skills, raising safety risks that resemble alcohol intoxication. Clinicians currently lack an objective biochemical test to determine when someone is dangerously... Read more
Simple Dual-Tau Blood Test Detects and Stages Alzheimer’s Disease
Alzheimer’s disease is typically confirmed and staged with positron emission tomography scans and cerebrospinal fluid testing, procedures that are costly and invasive. Broader access to minimally invasive... Read more
Alzheimer’s Blood Biomarkers Linked to Early Cognitive Differences Before Dementia
Blood-based screening for Alzheimer’s disease offers a noninvasive, lower-cost alternative to brain imaging or spinal fluid testing, yet its ability to flag the earliest cognitive changes has been unclear.... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channelAptamer-Based Biosensor Enables Mutation-Resilient SARS-CoV-2 Detection
Rapid evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can undermine existing molecular diagnostics, especially when assays target small viral components. Double-antibody sandwich... Read more
Study Points to Autoimmune Pathway Behind Long COVID Symptoms
Long COVID leaves many SARS-CoV-2 survivors with persistent fatigue, cognitive issues, palpitations, and musculoskeletal pain for months or years. Estimates cited in new research suggest 4%–20% of infected... Read more
Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read moreMicrobiology
view channel
New Culture Medium Speeds C. difficile Resistance Detection and Reduces Costs
Clostridioides difficile infections remain a persistent threat in hospitals and communities, affecting about 500,000 people in the United States each year. Severe cases can be fatal within 30 days of diagnosis,... Read more
Automated Blood Culture System Speeds Detection of Bloodstream Infections
Bloodstream infections and sepsis require rapid laboratory detection to guide targeted antimicrobial therapy and reduce mortality. Conventional blood culture workflows can delay actionable results by critical... Read morePathology
view channel
AI Pathology Tool Predicts Meningioma Recurrence from Routine Slides
Meningiomas are the most common primary brain tumors in adults, yet their course ranges from indolent to highly recurrent disease. Estimating an individual patient’s recurrence risk often requires advanced... Read more
3D Spatial Multi-Omics Maps Intra-Tumor Diversity in Colorectal Cancer
Colorectal cancer remains a leading cause of cancer death, and clinical decision-making is complicated by marked intra-tumor heterogeneity. Conventional bulk sequencing averages molecular signals across... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel
Genetic Testing Program Expands Detection of Alpha-1 Antitrypsin Deficiency
Alpha-1 Antitrypsin Deficiency (AATD) is a progressive genetic condition, the leading known genetic risk factor for chronic obstructive pulmonary disease (COPD), and a cause of liver disease in both children... Read more








